Foghorn Therapeutics (FHTX) EBT Margin: 2020-2025
Historic EBT Margin for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -202.00%.
- Foghorn Therapeutics' EBT Margin rose 4290.00% to -202.00% in Q3 2025 from the same period last year, while for Sep 2025 it was -305.82%, marking a year-over-year increase of 4392.00%. This contributed to the annual value of -383.24% for FY2024, which is 10744.00% down from last year.
- Foghorn Therapeutics' EBT Margin amounted to -202.00% in Q3 2025, which was up 18.75% from -248.62% recorded in Q2 2025.
- Foghorn Therapeutics' EBT Margin's 5-year high stood at -77.85% during Q3 2023, with a 5-year trough of -65,268.29% in Q3 2021.
- Over the past 3 years, Foghorn Therapeutics' median EBT Margin value was -339.73% (recorded in 2025), while the average stood at -371.08%.
- As far as peak fluctuations go, Foghorn Therapeutics' EBT Margin tumbled by 5,482,639bps in 2021, and later skyrocketed by 6,487,985bps in 2022.
- Quarterly analysis of 5 years shows Foghorn Therapeutics' EBT Margin stood at -3,998.32% in 2021, then surged by 330,793bps to -690.39% in 2022, then soared by 30,696bps to -383.43% in 2023, then plummeted by 29,945bps to -682.88% in 2024, then surged by 4,290bps to -202.00% in 2025.
- Its EBT Margin was -202.00% in Q3 2025, compared to -248.62% in Q2 2025 and -339.73% in Q1 2025.